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ST3GAL3 Mutations Impair the Development
of Higher Cognitive Functions
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Klaus Wrogemann,3 Kimia Kahrizi,4 Andreas Tzschach,1 Masoumeh Hosseini,4 Ideh Bahman,4
Tim Hucho,1 Martina Mu¨hlenhoff,2 Rita Gerardy-Schahn,2 Hossein Najmabadi,4 H. Hilger Ropers,1
and Andreas W. Kuss1,6,*
The genetic variants leading to impairment of intellectual performance are highly diverse and are still poorly understood. ST3GAL3
encodes the Golgi enzyme b-galactoside-a2,3-sialyltransferase-III that in humans predominantly forms the sialyl Lewis a epitope on
proteins. ST3GAL3 resides on chromosome 1 within the MRT4 locus previously identified to associate with nonsyndromic autosomal
recessive intellectual disability.We searched for the disease-causingmutations in theMRT4 family and a second independent consanguin-
eous Iranian family by using a combination of chromosome sorting and next-generation sequencing. Two different missense changes in
ST3GAL3 cosegregatewith the disease butwere absent inmore than 1000 control chromosomes. In cellular and biochemical test systems,
these mutations were shown to cause ER retention of the Golgi enzyme and drastically impair ST3Gal-III functionality. Our data provide
conclusive evidence that glycotopes formed by ST3Gal-III are prerequisite for attaining and/or maintaining higher cognitive functions.Introduction
Intellectual disability (ID) is a cognitive impairment
disorder characterized by an intelligence quotient (IQ)
below 70.1 Patients are persistently slow learners of basic
language and motor skills during childhood and show
significant subnormal global intellectual capacity as adults.
ID is thought to occur with a prevalence between 1% and
3% and frequently results from genetic aberrations (see
e.g., Ropers2). In developed countries the occurrence of
ID with (syndromic ID) or without (nonsyndromic ID)
other congenital anomalies is the most frequent reason
for seeking clinical advice. However, the cases where defin-
itive molecular alterations can be linked with ID represent
a minority (see e.g., Ropers3), per se reflecting the extreme
heterogeneity of genetic and environmental components
that are involved in the etiology of this disorder. In the
current study, we identified mutations in the sialyltransfer-
ase ST3GAL-III4 that cause nonsyndromic autosomal
recessive ID (NSARID), and with this discovery move the
glycocalyx, the outermost structure of each animal cell,5
into the focus of cognitive research.
Although largely neglected, the glycocalyx is without
doubt the essential information carrier in all living
systems. Only sugars, the molecular building blocks of
the glycocalyx, possess the chemical potential to create
a biological communication system that is rich enough
to store and translate the myriads of details for steering
and fine-tuning developmental processes in general6 and
neurodevelopment in particular.7 Indeed, glycosylation1Department for HumanMolecular Genetics, Max-Planck Institute forMolecula
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The Americandefects in general were previously reported to play a role
in the etiology of disorders with ID features including
NSARID (for reviews see e.g., Grunewald et al.8 and Mar-
quadt and Denecke9).10,11
In contrast to RNA, DNA, and protein biosynthesis,
glycans are built without guiding templates and thus are
prone to dynamic- and context-dependent alterations
reflecting the state of the respective individual cell (for
review see Cohen and Varki12).
Positioned at the outermost sites of the glycocalyx, the
nine-carbon-sugar sialic acid (Sia) plays a prominent role
in this scenario.13 The sialome, defined here as the total
complement of sialo-glycotopes, is built by twenty sialyl-
transferases (STs) that vary in acceptor and linkage speci-
ficity.14 Complementing this, modern organisms have
developed a large family of Sia-binding lectins to decipher
the information encrypted in the sialome (for review see
Crocker et al.15). Moreover, the recent evolution of the sia-
lylation pathway in humans has been leading to the gener-
ation of ten uniquely human variants within the ~60 genes
directly involved in the biosynthesis of the sialome.16 This
burst of genetic changes coincides with the separation of
the modern humans from their closest hominide relatives,
the great apes.17
ST3GAL3 located on chr1p34.1 encodes the b-galacto-
side-a2,3-sialyltransferase-III (ST3Gal-III), which in hu-
mans predominantly forms the sialyl Lewis a (sLea) epitope
on glycoproteins (see Figure 1).18 The gene maps to over-
lapping linkage intervals recently identified in two families
with members suffering from nonsyndromic autosomalr Genetics, 14195 Berlin, Germany; 2Institute for Cellular Chemistry, Hann-
y & Medical Genetics, University of Manitoba, Winnipeg R3E OJ9, Canada;
ences, Tehran 1985713834, Iran
ld and Interfaculty Institute for Genetics and Functional Genomics, Ernst
Genetics. All rights reserved.
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Figure 1. Schematic Representation of ST3GAL3 and the Major Translation Product Isoform B1
(A) ST3GAL3 is a complex transcriptional unit comprising 15 exons, 12 of which (dark gray boxes) contain protein coding sequence. The
major translation product is isoform B1. As a typical Golgi-localized sialyltransferase ST3Gal-III contains a short, N-terminally localized
cytoplasmic tail followed by a TMD (shaded in yellow). Positions of identified homozygous mutations and resulting amino acid
exchanges are indicated by arrows. The highly conserved sialylmotifs are shaded in green.
(B and C) Illustration of ST3Gal-III expression constructs used in this study to analyze the impact of mutations. All constructs are based
on isoform B1. Full-length sequences were extended by a C-terminal Myc-epitope to enable protein identification in the cellular context
and in parallel to compartmental markers. For the generation of soluble proteins the first 40 amino acids were replaced by protein A.
Construct names are indicated and mutations are highlighted by asterisks.
(D) ST3Gal-III is involved in the formation of the sialyl Lewis a (sLea) epitope on proteins. The transfer of sialic acid (Sia) onto galactose
(Gal) present in type I and II structures precedes the transfer of fucose (Fuc) to the core sugar N-acetylglucosamine (GlcNAc).recessive intellectual disability (NSARID).19,20 The identi-
fied intervals were 10.1 Mbp and 9.3 Mbp in size and
showed highly significant LOD scores of 4.2 and 7.1,
respectively. The shared common region was 7.9 Mbp
and contained a total of 118 protein coding genes,
including ST3GAL3.19,20 In each interval we identified
a different mutation in ST3GAL3, both of which cosegre-
gate with NSARID and have a deleterious impact upon
the functionality of the gene product.Subjects and Methods
Patients
This study was performed in accordance with the ethical standards
of the responsible institutional and national committees on
human experimentation. The patients and their families were re-
cruited in collaboration with local genetic counselors from Iran
who obtained informed consent of the parents from both families
in writing. Probands were examined by experienced clinical genet-
icists who assessed their physical andmental status by using a stan-
dard clinical evaluation form that had been designed as described
earlier.20 The family pedigrees are shown in Figure 2 and clinical408 The American Journal of Human Genetics 89, 407–414, Septembfeatures of the patients from both families are listed in Table S2,
available online.Genome Partitioning and Mutation Screening
We obtained a blood sample from one patient per family (1721 of
M096 and 381of M319) and used it to generate Epstein-Barr-Virus-
transformed lymphoblastoid cell lines (LCLs); we used these LCLs
to enrich chromosome 1 containing the genomic region previ-
ously identified to cosegregate with the disease.19,20 The chromo-
some sorting was performed by Chrombios (Raubling, Germany)
and resulted in about 300,000 metaphase copies of chromosome
1s per patient. DNAwas prepared and sequenced with an Illumina
Genome Analyzer IIx. Original sequencing data were deposited in
the Sequence Read Archive SRA (see Web Resources), accession
number SRA026713.
We next aligned the 36 bp paired-end reads obtained from each
sequencing run onto the human reference genome (hg18) and
focused for mutation screening on the target regions defined by
the linkage intervals of each family by using SOAP2.2021 and
the parameter settings –a –b –D –o –m 200 –x 6002 –g 3 –e. Reads
that could be unambiguously aligned to the target regions were
then used for variant calling, that is, the detection of nonsynony-
mous mutations located in coding regions and changes iner 9, 2011
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Figure 2. Family Pedigrees
Filled symbols indicate individuals suffering from intellectual
disability.canonical splice sites (based on the RefSeq gene model). We
excluded variants with a potential effect on splice sites (i.e., de-
stroying an existing splice site or introducing a cryptic splice
site) by using NNSplice (see Web Resources). Putatively causative
mutations located in untranslated regions or introns were
excluded by comparison with known regulatory elements from
the ORegAnno and TargetScan miRNA regulatory site databases
(see Web Resources). Variant calls had to be supported by at least
three nonidentical reads, a phred-like quality scoreR 20, and an
allelic percentage R 70. To remove neutral polymorphisms, vari-
ants were filtered with dbSNP130 as well as the published genomes
from 185 individuals22 and 200 Danish exomes.23
Expression Plasmids
We amplified the cDNA encoding the B1 isoform of ST3Gal-III
(accession number NM_006279.2) by PCR on cDNA purchased
fromOrigene (RC208261) and cloned it into pcDNA3 (Invitrogen)
to generate untagged full-length or into pcDNA3.1-Myc/His A
(Invitrogen) to generate C-terminally Myc-His6 tagged translation
products. Mutations were introduced by site-directed mutagen-
esis. Details on the used primer sequences are given in Table S1.
For the construction of soluble ProtA-tagged enzyme variants,
the sequence encoding amino acids 41–375 of ST3Gal-III was
amplified by PCR with Origene RC208261 as a template and
the resulting PCR product subcloned into pPROTA vector.24 The
p.Asp370Tyr mutant enzyme was generated by site-directed
mutagenesis. Detailed information on the cloning strategies is
given in Table S3.
Cell Culture and Transfection
The mouse fibroblast cell line LMTK and Chinese hamster ovary
(CHO) cells were cultured in DMEM/Ham’s F-12 (1:1) medium
(Biochrom) containing 5% FCS and 2 mM sodium pyruvate.The AmericanTransient transfections with plasmid DNAs were carried out with
Lipofectamine (Invitrogen) in OpitMEM (GIBCO BRL). EBV-trans-
formed lymphoblasts were cultured in RPMI 1640 medium
(Biochrom) containing 10% FCS, 2 mM sodium pyruvate,
100 U/ml penicillin and 0.1 mg/ml streptomycin.
Immunocytochemistry
Transiently transfected LMTK cells were fixed 72 hr after trans-
fection with 4% PFA (AppliChem) in PBS for 30 min at room
temperature, permeabilised with 0.2% Triton X-100 in PBS for
30 min, and incubated with primary antibodies for 1 hr. Rabbit
a-Mannosidase II antiserum (kindly provided by Kelley Moremen,
University of Georgia, Athens, USA) was used in a dilution of
1:8570, rabbit IRE1 polyclonal antibody (Abcam) in a dilution of
1:40, Myc antibody 9E10 (Roche) in a concentration of 5 mg/ml,
and ST3Gal-III antibody (Sigma, av46706) in a concentration of
2 mg/ml. Cells were stained with a combination of 1:2000 diluted
Cy3 conjugated sheep anti-mouse IgG (whole molecule) F(ab)2
fragments (Sigma) and 1 mg/ml Alexa Fluor 488 donkey anti-rabbit
IgG (HþL; Invitrogen Molecular Probes) or 1:1000 diluted Cy3
conjugated sheep anti-rabbit IgG (whole molecule) F(ab)2
fragments (Sigma) for 1 hr at room temperature in the dark.
Slides were mounted in Vectashield mounting medium with
40-6-Diamidino-2-phenylindole (DAPI) (Vector laboratories) and
analyzed with a Plan Apochromat 63x/1.40 Oil DIC M27 differen-
tial interference contrast objective with an Axiovert 200M micro-
scope in combination with an ApoTome, an AxioCAM MRm
digital camera and AxioVision 4.5 software (Zeiss). Images were
taken in an automatic exposure setting with filter sets for DAPI,
Alexa Fluor 488, and Cy3 and converted in blue, green, and red,
respectively. Intensities were adapted to be equal for the three
colors.
Immunoprecipitation
Soluble ProtA fusion constructs were extracted from cell culture
supernatants of transiently transfected CHO cells by the use of
IgG Sepharose Fast Flow 6 (GE Healthcare). Myc-tagged full-length
constructs were immunoprecipitated from CHO cell lysates by the
use of anti-Myc mAb 9E10 coupled to Protein G Sepharose Fast
Flow 4 (GE Healthcare). Protein concentrations were determined
by immunoblotting against the Myc-epitope with serial dilutions
of a purified Myc-tagged protein.
Immunoblot Analysis
Following a 5 min boiling step, samples were subjected to 10%
SDS-PAGE according to Laemmli25 under reducing conditions
with 2.5% (v/v) b-mercaptoethanol, and transferred onto nitrocel-
lulose membranes (Schleicher and Schuell) by immunoblotting.
For expression analysis, membranes were developed as described
in Mu¨hlenhoff et al.26 For the activity assay, membranes were
blocked with Odyssey Blocking Buffer (LI-COR,1:2 diluted in
PBS), incubated with penta-His antibody (QIAGEN) or mouse
IgG (Pierce) as described above, followed by incubation with
1:10,000 diluted anti-mouse IRDye680 (LI-COR) for 1 hr, and
analyzed with an Odyssey Imaging System (LI-COR). Bands were
quantified with the Odyssey 2.1 software.
Enzymatic Testing of ST3Gal-III Variants
ST3Gal-III variants immunoprecipitated as described above were
equilibrated with reaction buffer (50 mM 2-(N-morpholino)
ethanesulfonic acid (MES) [pH 6.5] and 10 mM MnCl2) andJournal of Human Genetics 89, 407–414, September 9, 2011 409
Table 1. Deep Sequencing Data
Patient/
Family
Total
Accumulative Length
of Obtained Sequence
Fragments [Gb]
Total Accumulative
Length of Mappable
Fragments [Gb]
Physical
Coordinates
of Linkage
Intervala [bp]
Total Accumulative
Length of Mappable
Fragments in Linkage
Interval [Mb]
Relative Sequence
Coverage in
Linkage Interval
Fold Coverage in
Linkage Interval
M096 7.43 6.81 chr1:37058812-
46775726
166 99.7% 17
M319 10.66 9.02 chr1:38895940-
48981455
246 99.4% 24
a Based on NCBI genome build 36.1 (hg18).subsequently, incubated with the synthetic acceptor Gal-
b1,3-GlcNAc-b-para-nitrophenol (1mM) and 50 mM (0.9 kBq)
CMP-[14C]Neu5Ac at 37C. After 1h, the reaction mix was loaded
onto methanol-activated SepPak Plus C18-columns (Waters). The
columns were washed three times with PBS, and reaction products
were eluted with 4.5 ml MeOH. Eluates were air-dried, resolved
in 3 ml Filtersafe scintillation cocktail (Zinsser Analytic), and
measured in an LS 6500Multi-Purpose ScintillationCounter (Beck-
man Coulter).Results
To identify the disease-causing mutations in the two
families with overlapping linkage intervals on chr1p34.1,
we used flow sorting to isolate in excess of 300,000
copies of chromosome 1 from LCLs of each index patient.
DNA preparations from these chromosomes were
submitted to high-throughput sequencing with a Genome
Analyzer IIx (Illumina), resulting in a sequence coverage of
more than 99% with a mean depth between 17 and 24
reads per bp position on chromosome 1 for the each
patient (Table 1). Alignment (with SOAP21) of the
mappable paired-end reads from the each linkage interval
with the human reference genome revealed 6384 (M096)
and 4874 (M319) homozygous sequence changes.
After in silico filtering of these data, 197 (M096) and 187
(M319) previously unreported DNA variants remained;
however, all but one mutation per family lay outside the
protein coding sequences as well as canonical splice donor
and acceptor sites. The single remaining change in each
patient affected the same gene, ST3GAL3, at positions
either in exon 2 (NM_006279.2: c.38C>A, p.Ala13Asp) or
exon 14 (NM_006279.2: c.1108G>T, p.Asp370Tyr; see
also Figure 1, Table S1), this change affected the transmem-
brane domain (TMD) and the catalytic domain (CD),
respectively. In silico analyses carried out with different
bioinformatic tools (Pmut,27 SIFT,28 and MutationTaster29)
suggested a disease-causing potential for both changes.
The mutations were confirmed by Sanger sequencing and
shown to be present in patients in a homozygous state
and heterozygous or absent in all tested healthy individ-
uals from each pedigree. In contrast, the newly identified
ST3GAL3 mutations appeared neither in the 278 copies
of chromosome 1 from ethnically matched controls nor
in the published genomes of 185 individuals from the410 The American Journal of Human Genetics 89, 407–414, Septemb1000 Genomes Project22 and were also absent in the
exomes of 200 Danish individuals,23 in whom no other
deleterious mutation within the whole coding region of
ST3GAL3 was also not observed.
Like all other members of the ST family, ST3Gal-III is
a Golgi-resident type II membrane protein30,31 containing
four highly conserved sialylmotifs that form part of the
active site32 (Figure 1). The ST3GAL3 mutations identified
in NSARID patients introduce primary sequence changes
in the TMD (ST3Gal-IIIAla13Asp) and the CD (ST3Gal-
IIIAsp370Tyr) outside of the conserved motifs (Figure 1). We
first investigated the presence of ST3GAL3 transcripts in
normal human lymphoblastoid cell lines by RT-PCR and
found extremely low expression in this cell type (data
not shown). Thus, facing a lack of suitable patient speci-
mens to study the consequences of these mutations
directly, we used cellular and in vitro test systems.
Because the TMDs of several glycosyltransferases have
previously been demonstrated to be involved in correct
subcellular localization of the enzymes (reviewed in Tu
and Banfield33), we suspected that the p.Ala13Asp muta-
tion affected ST3Gal-III localization. To test this, we ex-
pressed full-length forms of ST3Gal-IIIwt and the mutants
ST3Gal-IIIAla13Asp and ST3Gal-IIIAsp370Tyr in the murine
fibroblast cell line LMTK and evaluated the subcellular
localization of the enzymes by indirect immunofluores-
cence by using a ST3Gal-III-specific antibody. Notably,
the perinuclear Golgi signal obtained for the wild-type
enzyme was replaced by bright signals highly reminiscent
of ER staining in cells expressing one of the mutant
enzymes (Figure 3, left panel). To further explore this aber-
rant localization, we used C-terminally Myc-tagged
ST3Gal-III variants (ST3Gal-III-Myc), enabling the parallel
staining of compartmental markers (a-Mannosidase II
[a-Man II] for Golgi and IRE1 for ER). In keeping with the
direct detection of ST3Gal-III, the antibody recognizing
the Myc-tag demonstrated strict Golgi localization for
ST3Gal-IIIwt-Myc (overlay with anti-a-Man II), whereas
both mutants colocalized with the ER marker IRE1.
Remarkably, the segregation between a-Man II and
ST3Gal-IIIAsp370Tyr-Mycwas complete, whereas in rare cases
ST3Gal-IIIAla13Asp-Myc reached the Golgi apparatus in this
cellular assay system (Figure 3,middle panel). In both cases,
ER retention prevents the encounter of ST3Gal-III with its
Golgi-localized substrates and thus causes loss of function.er 9, 2011
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Figure 3. Impaired Golgi Transport of Mutant ST3Gal-III
The subcellular localization of wild-type (wt) and mutant forms of ST3Gal-III (p.Ala13Asp and p.Asp370Tyr) was analyzed in transiently
transfected LMTK cells. Proteins were expressed without (first column; ST3Gal-III) or with C-terminally addedMyc-epitope (ST3Gal-III-
Myc). A rabbit polyclonal antibody (anti-ST3Gal-III) was used to visualize the untagged protein (first column). Cells transfectedwithMyc-
tagged ST3Gal-III variants enabled the parallel display of recombinant proteins (anti-Myc; red) and of ER (anti-IRE1; green) and Golgi
(anti-a-Mannosidase II, a-Man II; green)markers, respectively. ST3Gal-III proteins of wild-type sequence showed the typical Golgi pattern
and signals obtained for the recombinant protein fully overlapped with the Golgi marker a-Man II. In contrast, the mutant proteins
(p.Ala13Asp andp.Asp370Tyr) displayed an ER-like distribution and an extensive overlapwith the ERmarker IRE1. Remarkably, the segre-
gation from theGolgimarkerwas complete for the p.Asp370Tyrmutant,whereas a significant overlapwith theGolgimarker a-Man II was
observed for the p.Ala13Asp mutant. Nuclei were stained with 4,60diamidino-2-phenylindole (DAPI; blue). Scale bar: 20 mm.To address the question of a direct effect of the identified
mutations on ST3Gal-III activity, we determined the
specific activity of the enzymes. Myc-tagged constructs
(see Figure 1B) were immunoisolated from transiently
transfected cells and tested in a radioactive incorporation
assay. The specific activities calculated from five indepen-
dent experiments are shown in Figure 4A. Under these
in vitro conditions, in which compartmental borders are
destroyed and enzymes and substrates come into direct
contact, the TMD mutant behaved like the wild-type. In
contrast, the CD mutant (p.Asp370Tyr) was found to be
completely inactive.
Although STs are extensively studied enzymes, the exist-
ing information on structure-function relationships (for
review see Audry et al.14) does not provide an explanation
for the deleterious effect caused by p.Asp370Tyr. The
amino acid exchange lies outside of the functionally
important sialylmotifs in an area not known to be involved
in protein folding or function. Soluble variants for wild-
type and CD mutant were therefore generated to enable
enzyme testing outside the cellular environment. The
N-terminal 40 amino acids (encompassing the cytoplamic
tail and TMD of ST3Gal-III; see Figure 1C) were replaced
with Staphylococcus aureus protein A. Fusion constructs
(ProtA-D40-ST3Gal-IIIwt andProtA-D40-ST3Gal-IIIAsp370Tyr)
were expressed in CHO cells, and the time course of the
appearance of recombinant proteins in the supernatant
was monitored by immunoblotting (Figure 4B). Compared
to ProtA-D40-ST3Gal-IIIwt, the secretion of ProtA-D40-
ST3Gal-IIIAsp370Tyr was drastically reduced (Figure 4B).
Notably, however, this lack of secretion did not correspondThe Americanwith an intracellular protein accumulation. In contrast,
similar intracellular expression levels observed for mutant-
and wt-protein argue for equal translation rates, which, in
the case of the mutant, might be followed by a rapid clear-
ance of the defective protein by the ER-associated quality
control system (for review see e.g., Hoseki et al.34 and Jar-
osch et al.35). Still, sufficient protein could be isolated and
used for in vitro testing. A representative experiment is
shown in Figure 4C and confirms that p.Asp370Tyr dramat-
ically affects the enzymatic function of ST3Gal-III.
Although the lack of structural information prevents the
molecular interpretation, this naturally occurringmutation
highlights another aspect of structure-function-relation-
ships in the family of sialyltransferases.Discussion
Sialic acids are key elements in cellular communication
processes because of their exposed position and unique
physiochemical properties. Consequently, genetic alter-
ations that disturb or prevent the formation of sialo-glyco-
conjugates are embryonic lethal (E 6.5 inmouse36) or cause
the development of diseases.37
In this study, we demonstrate a link between ST3Gal-III
activity and the establishment of higher brain functions.
By means of linkage analysis, chromosome sorting and
next-generation sequencing, we were able to identify
two mutations in ST3GAL3 cosegregating with NSARID,
which affect cellular localization and the activity and
abundance of the gene product ST3Gal-III. Although thisJournal of Human Genetics 89, 407–414, September 9, 2011 411
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Figure 4. Expression and Functional
Testing of Wild-Type and Mutant
ST3Gal-III
(A) Sialyltransferase activity of Myc-tagged
full-length enzyme variants. Wild-type
and mutant enzymes were immunoprecip-
itated from cell lysates of transiently trans-
fected CHO cells and tested for enzymatic
activity with the radioactively labeled
substrate CMP-[14C]Neu5Ac and the type
I acceptor Gal-b1,3-GlcNAc-b-para-nitro-
phenol (see Figure 1D). Incorporated
radioactivity was measured by scintillation
counting after purification with C18
columns. Activities were calculated from
five independent experiments and are
shown as mean values 5 standard error
of the mean.
(B) Expression analysis of secreted ProtA-
D40-ST3Gal-III variants. CHO cells were
transiently transfected and the appearance
of recombinant proteins in the cell culture
supernatants (upper panel) and cell lysates
(lower panel) was monitored over 72 hr by
immunoblotting.
(C) Sialyltransferase activity of secreted
ProtA-D40-ST3Gal-III variants. Wild-type and mutant enzymes were immunoprecipitated from cell culture supernatants of transiently
transfected CHO cells and the activity incorporation assay was performed as described in (A). One third of the immunoprecipitated
samples was analyzed by immunoblotting against the Protein A-part to control the amounts of protein incorporated into the activity
assay. Data obtained from three independent experiments are shown as mean values þ/ standard error of the mean.sialyltransferase can act on both type I and type II acceptor
structures (Figure 1D), the human ST3Gal-III has been
demonstrated to exhibit a marked preference for type I
structures on glycoproteins.18,38 The resulting major
product, sLea (Figure 1D), is well described in the context
of immune reactions39 but has never been linked to neural
development and/or function. However, high isotranscript
numbers of ST3GAL3 with patterns distinctly different
from transcript patterns in all other tissues have been
observed in human fetal neural tissue40 and indicate
a role of ST3Gal-III activity in brain function.
The N-terminal part of glycosyltransferases, and in
particular the transmembrane domain, have been demon-
strated to be important for correct Golgi localization of the
enzymes.33 Because the biosynthesis of glycotopes is
a sequential process strictly dependent on the vectorial
organization of enzymes in the ER and Golgi, the
ST3Gal-III glycan acceptor structures (see Figure 1D) are
formed by glycosyltransferases that are localized in the
Golgi.30,31 Moreover, provision of metabolically activated
sialic acid, the sugar donor substrate used by sialyltrans-
ferases, is restricted to the late Golgi compartments.41
Accordingly, correct localization in the Golgi apparatus is
a prerequisite for ST3Gal-III activity. The charged amino
acid residue introduced into the hydrophobic TMD in
ST3Gal-IIIAla13Asp is likely to disturb the transport informa-
tion eventually leading to ER retention. The partial rescue
of Golgi localization of ST3Gal-IIIAla13Asp-Myc relates to
the massive overexpression of the mutant enzyme in tran-
siently transfected cells. However, in the natural situation
where glycosyltransferases are generally low expressed412 The American Journal of Human Genetics 89, 407–414, Septemb(for review see Roth42), the complete loss of ST3Gal-III
activity is highly likely.
Fully unexpected was the finding that the very C-termi-
nally located p.Asp370Tyr mutation abolished forward
transport of ST3Gal-IIIAsp370Tyr to the Golgi apparatus
and prevented secretion of the construct ProtA-D40-
ST3Gal-IIIAsp370Tyr. This mutation that concerns a protein
segment outside the sialylmotifs14 seems to impact protein
folding and/or stability. As no accumulation in the ER
could be observed by immunoblot analysis, we assume
that the severe misfolding of the enzyme triggers degrada-
tion by the ERAD system.35 It is important to emphasize
that this naturally occurring mutation has revealed a so
far unknown function of the C terminus in the folding
of functional ST3Gal-III.
Interestingly, no behavioral abnormalities were reported
for a previously investigated ST3Gal-III knockout mouse
model.43 This promotes the conclusion that highly
dynamic combinatorial functions, which are characteristic
for human cognitive processes and a priori absent in the
mouse are affected. Moreover, in contrast to the known
congenital glycosylation disorders,8,9,44 patients with
ST3Gal-III mutations do not show any clinical features
apart from ID. Thus, it is tempting to speculate that periph-
eral functions of ST3Gal-III, as for instance described
in the mouse,45 are compensated in humans by other
members of the ST3Gal family.14 However, higher brain
functions have a complex molecular basis and particularly
the cognitive aspects thereof represent an evolutionarily
young feature. It can thus be assumed that functional
redundancy to secure the system against the loss ofer 9, 2011
individual components is not as developed as in older
features. This might explain why we find ST3Gal-III and
products of ST3Gal-III catalysis indispensable for higher
cognition in humans. In this context, it is also of note
that recent findings implicate sialylation in the modula-
tion of voltage-gated neuronal potassium channels,46
which seem to play a role in the etiology of psychiatric
symptoms and autism as well.47–49 We therefore conclude
that our results constitute an important contribution to
the understanding of the molecular basis of ID and other
autism spectrum disorders. What is more, by implicating
glycobiological aspects that were so far not considered to
play a role in the etiology of cognitive dysfunction, our
findings open up interesting new avenues of research
into the function of the human central nervous system
in health and disease.Supplemental Data
Supplemental Data include four tables and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
We are grateful to the patients and their families for their partici-
pation in the study. We thank Herbert Hildebrandt for helpful
discussion and Corinna Jensen, Marianne Schlicht, Anna-Maria
Baumann, and Maike Hartmann for expert technical assistance.
This work was supported financially by a grant from the Iranian
National Science Foundation. Support was also received from the
Max Planck Innovation Fund, a grant from the German Federal
Ministry of Education and Research to H.H.R. (MRNET
01GS08161-2), and a grant from the German Research Foundation
to R.G.-S. (GE 801/10-1). H.H.R., H.N., and K.K. participate in the
GENCODYS Consortium.
Received: June 16, 2011
Revised: August 2, 2011
Accepted: August 17, 2011
Published online: September 8, 2011Web Resources
The URLs for data presented herein are as follows:
NNSplice, http://www.fruitfly.org/seq_tools/splice.html
Online Mendelian Inheritance in Man (OMIM), http://omim.org
ORegAnno and TargetScan miRNA regulatory site databases,
http://genome.ucsc.edu/cgi-bin/hgTables
Sequence Read Archive (SRA), http://www.ncbi.nlm.nih.gov/sraAccession Numbers
The Sequence Read Archive (SRA) accession number for the
sequencing data reported in this paper is SRA026713.References
1. Ropers, H.H., and Hamel, B.C. (2005). X-linked mental retar-
dation. Nat. Rev. Genet. 6, 46–57.The American2. Ropers, H.H. (2008). Genetics of intellectual disability. Curr.
Opin. Genet. Dev. 18, 241–250.
3. Ropers, H.H. (2010). Genetics of early onset cognitive impair-
ment. Annu. Rev. Genomics Hum. Genet. 11, 161–187.
4. Kitagawa, H., and Paulson, J.C. (1993). Cloning and expres-
sion of human Gal beta 1,3(4)GlcNAc alpha 2,3-sialyltransfer-
ase. Biochem. Biophys. Res. Commun. 194, 375–382.
5. Varki, A., Cummings, R., Esko, J., Freeze, H., Hart, G., and
Marth, J.D. (1999). Essentials of Glycobiology (Cold Spring
Harbor, NY: Cold Spring Harbor Laboratory Press).
6. Haltiwanger, R.S., and Lowe, J.B. (2004). Role of glycosylation
in development. Annu. Rev. Biochem. 73, 491–537.
7. Kleene, R., and Schachner, M. (2004). Glycans and neural cell
interactions. Nat. Rev. Neurosci. 5, 195–208.
8. Grunewald, S., Matthijs, G., and Jaeken, J. (2002). Congenital
disorders of glycosylation: A review. Pediatr. Res. 52, 618–624.
9. Marquardt, T., and Denecke, J. (2003). Congenital disorders of
glycosylation: Review of their molecular bases, clinical presen-
tations and specific therapies. Eur. J. Pediatr. 162, 359–379.
10. Garshasbi, M., Hadavi, V., Habibi, H., Kahrizi, K., Kariminejad,
R., Behjati, F., Tzschach, A., Najmabadi, H., Ropers, H.H., and
Kuss, A.W. (2008). A defect in the TUSC3 gene is associated
with autosomal recessive mental retardation. Am. J. Hum.
Genet. 82, 1158–1164.
11. Molinari, F., Foulquier, F., Tarpey, P.S., Morelle, W., Boissel, S.,
Teague, J., Edkins, S., Futreal, P.A., Stratton, M.R., Turner, G.,
et al. (2008). Oligosaccharyltransferase-subunit mutations in
nonsyndromic mental retardation. Am. J. Hum. Genet. 82,
1150–1157.
12. Cohen, M., and Varki, A. (2010). The sialome—far more than
the sum of its parts. OMICS 14, 455–464.
13. Schauer, R. (2009). Sialic acids as regulators of molecular and
cellular interactions. Curr. Opin. Struct. Biol. 19, 507–514.
14. Audry, M., Jeanneau, C., Imberty, A., Harduin-Lepers, A.,
Delannoy, P., and Breton, C. (2011). Current trends in the
structure-activity relationships of sialyltransferases. Glycobi-
ology 21, 716–726.
15. Crocker, P.R., Paulson, J.C., and Varki, A. (2007). Siglecs and
their roles in the immune system. Nat. Rev. Immunol. 7,
255–266.
16. Varki, N.M., Strobert, E., Dick, E.J., Jr., Benirschke, K., and
Varki, A. (2011). Biomedical differences between human and
nonhuman hominids: Potential roles for uniquely human
aspects of sialic acid biology. Annu. Rev. Pathol. 6, 365–393.
17. Varki, A. (2010). Colloquium paper: Uniquely human evolu-
tion of sialic acid genetics and biology. Proc. Natl. Acad. Sci.
USA 107 (Suppl 2 ), 8939–8946.
18. Weinstein, J., de Souza-e-Silva, U., and Paulson, J.C. (1982).
Sialylation of glycoprotein oligosaccharides N-linked to aspar-
agine. Enzymatic characterization of a Gal beta 1 to 3(4)
GlcNAc alpha 2 to 3 sialyltransferase and a Gal beta 1 to
4GlcNAc alpha 2 to 6 sialyltransferase from rat liver. J. Biol.
Chem. 257, 13845–13853.
19. Kuss, A.W., Garshasbi, M., Kahrizi, K., Tzschach, A., Behjati, F.,
Darvish, H., Abbasi-Moheb, L., Puettmann, L., Zecha, A.,
Weissmann, R., et al. (2011). Autosomal recessive mental
retardation: homozygosity mapping identifies 27 single
linkage intervals, at least 14 novel loci and several mutation
hotspots. Hum. Genet. 129, 141–148.
20. Najmabadi, H., Motazacker, M.M., Garshasbi, M., Kahrizi, K.,
Tzschach, A., Chen, W., Behjati, F., Hadavi, V., Nieh, S.E.,
Abedini, S.S., et al. (2007). Homozygosity mapping inJournal of Human Genetics 89, 407–414, September 9, 2011 413
consanguineous families reveals extreme heterogeneity of
non-syndromic autosomal recessive mental retardation and
identifies 8 novel gene loci. Hum. Genet. 121, 43–48.
21. Li, R., Yu, C., Li, Y., Lam, T.W., Yiu, S.M., Kristiansen, K., and
Wang, J. (2009). SOAP2: An improved ultrafast tool for short
read alignment. Bioinformatics 25, 1966–1967.
22. 1000 Genomes Project Consortium. (2010). A map of human
genome variation from population-scale sequencing. Nature
467, 1061–1073.
23. Li, Y., Vinckenbosch, N., Tian, G., Huerta-Sanchez, E., Jiang,
T., Jiang, H., Albrechtsen, A., Andersen, G., Cao, H., Kornelius-
sen, T., et al. (2010). Resequencing of 200 human exomes
identifies an excess of low-frequency non-synonymous
coding variants. Nat. Genet. 42, 969–972.
24. Sanchez-Lopez, R., Nicholson, R., Gesnel, M.C., Matrisian,
L.M., and Breathnach, R. (1988). Structure-function relation-
ships in the collagenase family member transin. J. Biol.
Chem. 263, 11892–11899.
25. Laemmli, U.K. (1970). Cleavage of structural proteins during
the assembly of the head of bacteriophage T4. Nature 227,
680–685.
26. Mu¨hlenhoff, M., Eckhardt, M., Bethe, A., Frosch, M., and Ger-
ardy-Schahn, R. (1996). Autocatalytic polysialylation of poly-
sialyltransferase-1. EMBO J. 15, 6943–6950.
27. Ferrer-Costa, C., Gelpı´, J.L., Zamakola, L., Parraga, I., de la
Cruz, X., and Orozco, M. (2005). PMUT: A web-based tool
for the annotation of pathological mutations on proteins.
Bioinformatics 21, 3176–3178.
28. Kumar, P., Henikoff, S., and Ng, P.C. (2009). Predicting the
effects of coding non-synonymous variants on protein func-
tion using the SIFT algorithm. Nat. Protoc. 4, 1073–1081.
29. Schwarz, J.M., Ro¨delsperger, C., Schuelke, M., and Seelow, D.
(2010). MutationTaster evaluates disease-causing potential of
sequence alterations. Nat. Methods 7, 575–576.
30. Roth, J., and Berger, E.G. (1982). Immunocytochemical local-
ization of galactosyltransferase in HeLa cells: Codistribution
with thiamine pyrophosphatase in trans-Golgi cisternae.
J. Cell Biol. 93, 223–229.
31. Burger, P.C., Lo¨tscher, M., Streiff, M., Kleene, R., Kaissling, B.,
and Berger, E.G. (1998). Immunocytochemical localization of
alpha2,3(N)-sialyltransferase (ST3Gal III) in cell lines and rat
kidney tissue sections: Evidence for golgi and post-golgi local-
ization. Glycobiology 8, 245–257.
32. Datta, A.K., Chammas, R., and Paulson, J.C. (2001).
Conserved cysteines in the sialyltransferase sialylmotifs form
an essential disulfide bond. J. Biol. Chem. 276, 15200–15207.
33. Tu, L., and Banfield, D.K. (2010). Localization of Golgi-resi-
dent glycosyltransferases. Cell. Mol. Life Sci. 67, 29–41.
34. Hoseki, J., Ushioda, R., and Nagata, K. (2010). Mechanism and
components of endoplasmic reticulum-associated degrada-
tion. J. Biochem. 147, 19–25.
35. Jarosch, E., Lenk, U., and Sommer, T. (2003). Endoplasmic
reticulum-associated protein degradation. Int. Rev. Cytol.
223, 39–81.
36. Schwarzkopf, M., Knobeloch, K.P., Rohde, E., Hinderlich, S.,
Wiechens, N., Lucka, L., Horak, I., Reutter, W., and414 The American Journal of Human Genetics 89, 407–414, SeptembHorstkorte, R. (2002). Sialylation is essential for early develop-
ment in mice. Proc. Natl. Acad. Sci. USA 99, 5267–5270.
37. Reinke, S.O., Lehmer, G., Hinderlich, S., and Reutter, W.
(2009). Regulation and pathophysiological implications of
UDP-GlcNAc 2-epimerase/ManNAc kinase (GNE) as the key
enzyme of sialic acid biosynthesis. Biol. Chem. 390, 591–599.
38. Kono, M., Ohyama, Y., Lee, Y.C., Hamamoto, T., Kojima, N.,
and Tsuji, S. (1997). Mouse beta-galactoside alpha 2,3-sialyl-
transferases: Comparison of in vitro substrate specificities
and tissue specific expression. Glycobiology 7, 469–479.
39. Kannagi, R., Ohmori, K., and Kimura, N. (2009). Anti-oligosac-
charide antibodies as tools for studying sulfated sialoglyco-
conjugate ligands for siglecs and selectins. Glycoconj. J. 26,
923–928.
40. Grahn, A., Barkhordar, G.S., and Larson, G. (2002). Cloning
and sequencing of nineteen transcript isoforms of the human
alpha2,3-sialyltransferase gene, ST3Gal III; its genomic organi-
sation and expression in human tissues. Glycoconj. J. 19,
197–210.
41. Eckhardt, M., Mu¨hlenhoff, M., Bethe, A., and Gerardy-
Schahn, R. (1996). Expression cloning of the Golgi CMP-sialic
acid transporter. Proc. Natl. Acad. Sci. USA 93, 7572–7576.
42. Roth, J. (1991). Localization of glycosylation sites in the Golgi
apparatus using immunolabeling and cytochemistry. J. Elec-
tron Microsc. Tech. 17, 121–131.
43. Ellies, L.G., Sperandio, M., Underhill, G.H., Yousif, J., Smith,
M., Priatel, J.J., Kansas, G.S., Ley, K., and Marth, J.D. (2002).
Sialyltransferase specificity in selectin ligand formation. Blood
100, 3618–3625.
44. Krasnewich, D., O’Brien, K., and Sparks, S. (2007). Clinical
features in adults with congenital disorders of glycosylation
type Ia (CDG-Ia). Am. J. Med. Genet. C. Semin. Med. Genet.
145C, 302–306.
45. Guo, J.P., Brummet, M.E., Myers, A.C., Na, H.J., Rowland, E.,
Schnaar, R.L., Zheng, T., Zhu, Z., and Bochner, B.S. (2011).
Characterization of expression of glycan ligands for Siglec-F
in normal mouse lungs. Am. J. Respir. Cell Mol. Biol. 44,
238–243.
46. Schwetz, T.A., Norring, S.A., Ednie, A.R., and Bennett, E.S.
(2011). Sialic acids attached to O-glycans modulate voltage-
gated potassium channel gating. J. Biol. Chem. 286, 4123–
4132.
47. Dhamija, R., Renaud, D.L., Pittock, S.J., McKeon, A., Lachance,
D.H., Nickels, K.C., Wirrell, E.C., Kuntz, N.L., King, M.D., and
Lennon, V.A. (2011). Neuronal voltage-gated potassium
channel complex autoimmunity in children. Pediatr. Neurol.
44, 275–281.
48. Parthasarathi, U.D., Harrower, T., Tempest, M., Hodges, J.R.,
Walsh, C., McKenna, P.J., and Fletcher, P.C. (2006). Psychiatric
presentation of voltage-gated potassium channel antibody-
associated encephalopathy. Case report. Br. J. Psychiatry
189, 182–183.
49. Kitten, S., Gupta, N., Bloch, R.M., and Dunham, C.K. (2011).
Voltage-gated potassium channel antibody associated mood
disorder without paraneoplastic disease. Biol. Psychiatry 70,
e15–e17.er 9, 2011
